AVP‐825 Breath‐Powered Intranasal Delivery System Containing 22 mg Sumatriptan Powder vs 100 mg Oral Sumatriptan in the Acute Treatment of Migraines (The COMPASS Study): A Comparative Randomized Clinical Trial Across Multiple Attacks

Publisher： John Wiley & Sons Inc

E-ISSN： 1526-4610|55|5|621-635

ISSN： 0017-8748

Source： HEADACHE, Vol.55, Iss.5, 2015-05, pp. : 621-635

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

A Randomized, Double‐Blind, Placebo‐Controlled Study of Breath Powered Nasal Delivery of Sumatriptan Powder (AVP‐825) in the Treatment of Acute Migraine (The TARGET Study)

By  

HEADACHE, Vol. 55, Iss. 1, 2015-01 ,pp. : 88-100

John Wiley & Sons Inc

Access to resources Recommend Favorite

AVP‐825 (Sumatriptan Nasal Powder) Reduces Nausea Compared to Sumatriptan Tablets: Results of the COMPASS Randomized Clinical Trial

By  

HEADACHE, Vol. 58, Iss. 2, 2018-02 ,pp. : 229-242

John Wiley & Sons Inc

Access to resources Recommend Favorite

A Randomized Trial Comparing the Pharmacokinetics, Safety, and Tolerability of DFN‐02, an Intranasal Sumatriptan Spray Containing a Permeation Enhancer, With Intranasal and Subcutaneous Sumatriptan in Healthy Adults

By  

HEADACHE, Vol. 56, Iss. 9, 2016-10 ,pp. : 1455-1465

John Wiley & Sons Inc

Access to resources Recommend Favorite

The Efficacy of Propofol vs. Subcutaneous Sumatriptan for Treatment of Acute Migraine Headaches in the Emergency Department: A Double‐Blinded Clinical Trial

By  

PAIN PRACTICE, Vol. 15, Iss. 8, 2015-11 ,pp. : 701-705

John Wiley & Sons Inc

Access to resources Recommend Favorite

Consistency of Response to Sumatriptan/Naproxen Sodium in a Randomized Placebo‐Controlled, Cross‐Over Study for the Acute Treatment of Migraine in Adolescence

By  

HEADACHE, Vol. 55, Iss. 4, 2015-04 ,pp. : 519-528

John Wiley & Sons Inc

Access to resources Recommend Favorite